BPC-157

BPC-157 (short for "body protection compound 157") is a synthetic pentadecapeptide, a chain of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), whose sequence was identified in a protective protein found in human gastric juice. The early work on it came from Predrag Sikiric's group at the University of Zagreb in Croatia, where it was studied under designations including PL-14736 (Sikiric et al., Curr Pharm Des, 2011 PMID 21548867).

Two properties explain why it became a research subject: it is unusually stable in gastric fluid (reported as remaining intact for over 24 hours, which is rare for a peptide), and the early animal work suggested broad tissue-repair effects rather than a single narrow action. It is most often discussed alongside soft-tissue injury research: tendons, ligaments, muscle, skin wounds, and the gastrointestinal tract.

Distinctions. BPC-157 is not the same as TB-500 (a fragment of the protein thymosin beta-4), though the two are frequently sold and marketed together online. They are different molecules with different research histories, and claims about one do not transfer to the other. It is also not related to semaglutide or other GLP-1 medicines despite appearing in the same online peptide marketplaces.

The research questions have been preclinical: does this peptide accelerate healing in injured tissue, and through what pathways? Specific lines of investigation include tendon and ligament healing in rats, muscle-to-bone reattachment, wound and burn healing, gastrointestinal injury (alcohol- and NSAID-induced lesions, intestinal anastomoses), blood-vessel growth (angiogenesis, the formation of new blood vessels), and interactions with the nitric-oxide signaling system. A 2025 systematic review of the orthopaedic literature screened 544 articles and included 36, 35 preclinical and 1 clinical (a retrospective case series), which gives a fair picture of where the field stands: deep in animals, essentially absent in humans (Vasireddi et al., HSS J, 2025 PMID 40756949).

No human efficacy studies were identified in our reviewed sources. There is no published, peer-reviewed randomized controlled trial of BPC-157 in humans for any indication: not for tendon healing, wound healing, gut injury, or anything else. This is not a gap in our search; it is the consistent finding of independent reviews through 2026, including a 2025 systematic review that found zero human trials among 36 included studies PMID 40756949 and a 2026 narrative review (Mateescu et al., Pharmaceutics PMID 42198317) describing a decade-long evidence vacuum after the only registered Phase 1 trial was cancelled without results.

What the human record actually contains, and why none of it establishes efficacy:

• Lee & Burgess (2025): an open-label pilot in which 2 healthy adults received intravenous BPC-157 (10 mg on day 1, 20 mg on day 2). No adverse effects were reported and monitored blood markers showed no measurable change PMID 40131143. With 2 participants, no control group, and no efficacy endpoints, this is a tolerability observation, not evidence of benefit.
• NCT02637284: a Phase 1 safety and pharmacokinetics trial in 42 healthy volunteers, registered on ClinicalTrials.gov in December 2015 by PharmaCotherapia. Its status is listed as unknown; it was reportedly cancelled in 2016 and no results were ever published. A registration is not a results paper.
• NCT07803250: a randomized, double-blind, placebo-controlled Phase 1 pilot trial of BPC-157 for recovery after arthroscopic rotator-cuff repair (University of Arkansas sponsor), registered September 2026; status not yet recruiting, estimated start January 2027. A registration is not a results paper.
• NCT07752381: an industry-sponsored single-arm study of BPC-157 peptide gummies (500 µg per serving) in 40 physically active adults, completed November 2025 with no results posted. Single-arm with no comparator group, so it cannot establish efficacy even when results appear.
• Retrospective knee-pain series: small uncontrolled observations (a 2021 series of 16 patients receiving knee injections of BPC-157 alone or combined with thymosin beta-4 (4 of 16 received the combination), which confounds attribution, PMID 34324435; a 2024 pilot of 12 women with interstitial cystitis receiving a single injection into or around the bladder wall during cystoscopy (10 mg total) PMID 39325560). Without control groups or blinding, symptom changes cannot be attributed to the compound.
• Veljaca et al. (2003): a conference abstract reporting safety and pharmacokinetics after rectal administration in healthy male volunteers (Gut, 52 Suppl VI:A246). An abstract is not a peer-reviewed paper, and no full publication followed.
• PL-14736 ulcerative-colitis trial: referenced in reviews as a Phase 2 human trial conducted in Croatia, reportedly showing no toxicity. The full trial data were never published as a standalone peer-reviewed paper, so the claim cannot be independently evaluated.

Most of the research so far comes from laboratory and animal studies. That does not tell us whether it works in people.

Absence of published human trials is not the same as proof the compound does nothing: it means no one can say, from reviewed evidence, what it does in people.

The preclinical literature is large and almost entirely from rodent models, with a heavy concentration of authorship in the originating Zagreb group, a limitation worth stating plainly, since independent replication is thin.

• Tendon healing (rats). Chang et al. (2011) reported that BPC-157 promoted tendon outgrowth and increased survival and migration of tendon fibroblasts (the cells that maintain tendon tissue), in both cell culture and a rat tendon-injury model (J Appl Physiol PMID 21030672, DOI: 10.1152/japplphysiol.00945.2010). Staresinic et al. (2003) reported accelerated healing of transected rat Achilles tendons and stimulated growth of tendon cells in vitro (J Orthop Res PMID 14554208).
• Ligament healing (rats). Cerovecki et al. (2010) reported improved healing of the medial collateral ligament in rats (DOI: 10.1002/jor.21107).
• Wound healing. Huang et al. (2015) reported that BPC-157 enhanced alkali-burn wound healing in animals and promoted proliferation, migration, and blood-vessel formation in cell cultures (Drug Des Devel Ther PMID 25995620, PMCID PMC4425239).
• Blood-vessel and nitric-oxide signaling. Hsieh et al. (2017) reported that BPC-157's pro-angiogenic effects in human endothelial cells and rats were associated with activation of the VEGFR2-Akt-eNOS pathway (VEGFR2 is a receptor that drives blood-vessel growth; eNOS is an enzyme that produces nitric oxide) (J Mol Med PMID 27847966).
• Preclinical toxicology. Xu et al. (2020) conducted a multi-species toxicology screen (mice, rats, rabbits, dogs) PMID 32334036. Animal toxicology cannot establish a safe human dose.

None of these findings has been confirmed in controlled human studies, and animal results are not human efficacy findings.

Tendon fibroblasts migrating faster in a dish, or a rat Achilles tendon healing faster, does not tell us what happens in a person's injured tendon: different biology, different dosing, different context.

The proposed mechanisms come entirely from cell and animal work: biological plausibility, not demonstrated human outcomes.

• Angiogenesis (new blood-vessel formation). BPC-157 has been reported to promote vessel growth in healing tissue, with the Hsieh et al. (2017) study linking the effect to VEGFR2 activation and downstream Akt-eNOS signaling PMID 27847966. Since blood supply is part of how tissue heals, this is offered as a reason the peptide might aid repair, but whether it changes healing in a person is untested.
• Nitric-oxide system interaction. Several rat studies report that BPC-157's effects interact with the nitric-oxide pathway (nitric oxide is a signaling molecule involved in blood-vessel tone and inflammation), including counteracting the effects of nitric-oxide blockers in injury models (Sikiric et al., 2011 PMID 21548867).
• Cell migration and survival. The tendon work reports increased fibroblast migration and survival under stress PMID 21030672, proposed as a cellular basis for the healing observations.

What is not known: there is no established human receptor, target, or pathway for BPC-157.

A mechanism observed in rat tissue or human cells in a dish is a hypothesis about people, not a finding about people.

Do not treat any pathway above as explaining a human benefit: no human benefit has been demonstrated.

The honest summary: the human safety profile is unknown. There is no adequate human safety dataset: no completed Phase 1 with published results, no dose-finding study, no long-term follow-up. The two-person pilot reported no adverse effects PMID 40131143; two people cannot establish safety. Animal toxicology exists but cannot establish a safe human dose.

Unanswered questions include:

• what dose, if any, is safe or active in people
• how BPC-157 is absorbed, distributed, and cleared in humans, because no peer-reviewed pharmacokinetic data exist
• its effects in pregnancy, children, older adults, or people with medical conditions
• the effects of long-term use

Interactions.

We did not find reliable interaction data in the sources reviewed. That does not mean there are no interactions.

One preclinical line of work reports interactions with the nitric-oxide system in rats PMID 21548867. That is a reason for caution in principle, not a usable interaction profile.

Product-quality risks. BPC-157 is sold online as a research chemical. It is not manufactured to pharmaceutical standards, and regulators on both sides of the border have flagged this channel.

FDA staff scientists concluded BPC-157 "lacks sufficient safety data and has not been shown to be safe or effective in humans" (as summarized by USADA).

In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 to the 503A Bulks List. The vote is advisory only. The FDA has not issued a rule, and compounding remains unauthorized.

In August 2026, the FDA issued warning letters to five online sellers of other unapproved peptides marketed as "research use only." The FDA found that dosing information and injection instructions on their sites established intended human use.

Health Canada has advised the public to think twice before injecting peptides bought online (Health Canada advisory).

Unverified purity, contamination, non-sterile injectables, and mislabeled contents are documented risks of this supply channel in general. A product page's claims do not resolve any of them.

Athletes. WADA lists BPC-157 under S0 (Non-Approved Substances). It is prohibited at all times, in and out of competition, with no therapeutic-use exemption. This is confirmed by USADA and by Sport Integrity Canada's April 2026 reminder that BPC-157 appears on the WADA 2026 Prohibited List.

What was studied, in what. Most of the literature consists of:

• rat injury models, including tendon transection, ligament injury, muscle detachment, burns, and gut lesions
• cell cultures involving tendon fibroblasts and human endothelial cells

Human observations are limited to the small pilots and case series described in the human-studies section.

Most animal research comes from a single research group. That limits independent confirmation.

Duration. Animal studies typically followed injuries for days to weeks. The human pilots followed participants for days. No long-term human data exist.

Formulations and routes. In animal studies, researchers administered BPC-157 depending on the model:

• by local injection near the injury
• systemically through intraperitoneal administration
• orally/intragastrically
• topically

The human pilots used intra-articular (joint) injection; injection into or around the bladder wall during cystoscopy; and intravenous infusion.

Routes used in animals do not establish appropriate or safe routes in people.

Doses. These are reported only as study history.

Animal studies used laboratory dosing scaled to rats and mice. In the single human pilot, researchers infused 10 mg on day 1 and 20 mg on day 2 intravenously in two adults PMID 40131143.

These numbers describe what researchers administered in those studies. They are not a protocol, not a recommended amount, and cannot be extrapolated. There is no established human dose.

United States. BPC-157 is not FDA-approved for any indication, in any formulation. It cannot be prescribed.

For compounding, FDA staff scientists highlighted the lack of clinical data on efficacy or safety. In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, along with five other peptides, to the 503A Bulks List.

The vote is advisory. The FDA must still complete formal rulemaking before any addition. As of the literature-search date, no rule has been issued, so compounding BPC-157 remains unauthorized.

Research-use-only labeling does not resolve the FDA's concerns about unauthorized products promoted for human use (FDA; FDA warning-letter listing). August 2026 warning letters to online peptide sellers reinforced that dosing information on a "research use only" site can establish intended human use.

Athletes: prohibited under WADA S0 at all times.

Canada. BPC-157 is not authorized by Health Canada for any indication. It cannot be prescribed.

Health Canada has publicly advised against injecting peptides bought online, noting unauthorized products and the problem of research-use labels on products promoted for human use (Health Canada advisory).

A vendor stating that it ships to Canada is not evidence that sale, importation, possession, or use is authorized.

Other countries. Reviewed coverage for this profile is US + Canada only. The country selector on the live site will show this limitation. We do not claim worldwide status.

There is no legal/illegal boolean here.

The reviewed facts are specific: no authorization in the US or Canada, no approved product to prescribe, anti-doping prohibition for athletes, and regulator warnings about the online supply channel.

No verification reports have been reviewed for this profile.

Straight Up Peptides has not purchased or commissioned testing of any BPC-157 sample as of the literature-search date. There is no independent testing badge, no sample record, and no lab report to inspect.

We do not seed public pages with invented reports, and none are invented here.

Here is what sample testing can and cannot establish, so readers can evaluate vendor claims they encounter elsewhere.

A certificate of analysis, or COA. A vendor COA typically reports identity, meaning whether the powder is the stated molecule, usually using mass spectrometry, and analytical purity, usually using HPLC, for the specific sample tested.

A COA can be supplier-submitted, meaning the vendor chose what to send, or independently commissioned. Those have very different evidentiary weight, and the distinction must be disclosed.

What a COA cannot establish:

• sterility
• endotoxin or bacterial toxin levels
• accurate fill mass per vial
• absence of contaminants
• clinical safety
• regulatory authorization

Analytical purity does not mean a product is safe to inject, accurately dosed, or legally sold.

Scope limits. Findings apply only to the tested sample and lot.

A passing report on one lot says nothing about the next lot, other products, or the vendor as a whole. "Not tested" must remain visible for every untested dimension.

Until the verification program purchases samples and publishes batch-specific reports with documented chain of custody, this section remains an explainer, not a record.

Matched research questions matter. So do the differences in evidence.

There are no winner badges here. Missing evidence stays visible.

BPC-157 vs. standard care for tendon/ligament injury. The research question is the same: "what helps an injured tendon heal?"

Rest and load management, physiotherapy, NSAIDs, and, for some injuries, surgery or platelet-rich plasma have human-trial evidence, each with its own reviewed literature.

BPC-157 has no human efficacy trials for any of these comparisons.

The honest comparison is straightforward: studied-in-humans options versus an option with no human data.

BPC-157 vs. TB-500 (thymosin beta-4 fragment). These compounds are frequently marketed together as a "stack," but they are distinct molecules.

We have not reviewed comparable trial data for TB-500 in this profile, so no efficacy comparison can be made.

Being sold together is a marketing fact, not evidence of combined effect. "No combination studies identified" cannot become "compatible."

BPC-157 vs. approved wound-care products. Prescription and over-the-counter wound-care products went through human testing for their labeled uses. BPC-157 has not.

These are different evidence universes. The comparison is the absence of one.

Is BPC-157 approved anywhere?

Not by the FDA, not by Health Canada, and not by any major regulatory authority in our reviewed sources. There is no approved BPC-157 product to prescribe.

If I buy it online marked "for research use only," is that legal/safe?

"For research use only" is a seller's label. It is not a safety determination or a legal authorization for personal use.

Regulators in both the US and Canada have specifically warned that research-use labeling does not resolve concerns about unauthorized products promoted for human use (FDA; FDA warning-letter listing; Health Canada advisory).

We have no verified quality data on any online BPC-157 product.

Does the lack of human trials mean it doesn't work?

No.

It means the question is unanswered.

Animal and cell findings are real findings about animals and cells. They are reasons to run human trials, not substitutes for them.

Anyone claiming proven human benefits is going beyond the reviewed evidence.

Can athletes use it?

No, if they are subject to anti-doping rules.

WADA lists BPC-157 as an S0 Non-Approved Substance, prohibited at all times with no therapeutic-use exemption.

Is it safe?

Unknown.

Two healthy adults tolerated IV infusions in a tiny pilot PMID 40131143. That cannot establish safety.

There is no established dose, no pharmacokinetic data, and no long-term data in people.

Why do so many animal studies exist but no human trials?

The 2026 translational literature (Mateescu et al., Pharmaceutics PMID 42198317) points to the cancelled 2015 Phase 1 trial (NCT02637284, no published results) as the pivotal break.

Without foundational human pharmacokinetic and safety data, dose selection and trial design for later studies had no basis. The field stalled while uncontrolled use grew.

A new university-sponsored pilot trial was registered in September 2026 (NCT07803250), but it has not started.

That is the history. It does not validate the uncontrolled use.

Reviewed references

All verified against PubMed unless noted. PMIDs link to pubmed.ncbi.nlm.nih.gov.

Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011. PMID 21548867. Narrative review (rat GI models; references the unpublished PL-14736 IBD trial).

Staresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21:976–83. PMID 14554208. DOI: 10.1016/S0736-0266(0300110-4. Animal + in vitro.

Veljaca M et al. BPC-157: Safety and pharmacokinetics after rectal administration in healthy male volunteers. Gut. 2003;52(Suppl VI):A246. Conference abstract only (not a peer-reviewed full paper).

Cerovecki T et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28:1155–61. DOI: 10.1002/jor.21107 Animal. (No PMID located; cited by DOI.)

Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110:774–80. PMID 21030672. DOI: 10.1152/japplphysiol.00945.2010 Animal + in vitro.

Huang T et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485–99. PMID 25995620. DOI: 10.2147/DDDT.S82030 PMCID PMC4425239. Animal + in vitro.

Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95:323–33. PMID 27847966. In vitro (HUVEC) + rat.

Xu et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. PMID 32334036. DOI: 10.1016/j.yrtph.2020.104665 Animal toxicology (mice, rats, rabbits, dogs; no serious toxicity reported).

Lee E, Padgett K. Retrospective series: intra-articular BPC-157 for knee pain. 2021. PMID 34324435. Uncontrolled human observation, n=16; BPC-157 alone or combined with thymosin beta-4 (4 of 16 received the combination), confounding attribution.

Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID 40756949. Systematic review: 544 screened, 36 included (35 preclinical, 1 clinical).

Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20–24. PMID 40131143. Open-label human pilot, n=2, safety/tolerability only.

Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12–17. PMID 39325560. Uncontrolled human pilot, n=12 women, single injection into/around the bladder wall during cystoscopy (10 mg total); no control group.

Mateescu DM et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. PMID 42198317. DOI: 10.3390/pharmaceutics18050625 Narrative review (the 2026 translational review cited for the evidence-vacuum analysis).

Trial-registry records

Via ClinicalTrials.gov:

NCT02637284. Phase 1 safety/pharmacokinetics in 42 healthy volunteers (PharmaCotherapia), registered December 2015; status unknown; no results published.

NCT07803250. Randomized, double-blind, placebo-controlled Phase 1 pilot of BPC-157 after arthroscopic rotator-cuff repair (University of Arkansas), registered September 2026; not yet recruiting; no results.

NCT07752381. Industry-sponsored single-arm study of BPC-157 gummies in 40 physically active adults (Parlay Wellness), completed November 2025; no results posted.

Regulatory/anti-doping sources

USADA, "BPC-157: Experimental Peptide Creates Risk for Athletes" (no human trials establishing efficacy; WADA S0; FDA briefing summary).

Sport Integrity Canada, "Reminder: Non-Approved Peptides Included on the Prohibited List," April 27, 2026 (BPC-157 named as S0 on the WADA 2026 Prohibited List).

FDA Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026 (advisory vote recommending BPC-157 and five other peptides for the 503A Bulks List; FDA staff had recommended against all seven; no rulemaking issued as of the search date).

FDA warning letters, August 2026, to five online sellers of unapproved peptides marketed as "research use only" (dosing information and injection instructions established intended human use).

Health Canada, "Think twice before injecting peptides bought online: unauthorized products can seriously harm you" (public advisory, April 9, 2026). https://recalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-bought-online-unauthorized-products-can-seriously-harm

FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (Dec 2023, updated June 15, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (URL returned 404 on 2026-10-06; the FDA appears to have moved the page after its June 2026 update).

FDA warning letter MARCS-CMS 695607 to Summit Research Peptides (Dec 10, 2024): "Despite statements on your product labeling marketing your products as 'RESEARCH USE ONLY'..., evidence obtained from your websites establish that your products are intended to be drugs for human use." Listed in FDA's 2024 Warning Letters - Health Fraud (https://www.fda.gov/consumers/health-fraud-scams/2024-warning-letters-health-fraud); full text mirrored at https://www.einpresswire.com/article/769704955/summit-research-peptides-695607-12-10-2024.

Methodology

Literature search: PubMed (title/abstract and MeSH searches for "BPC-157" / "pentadecapeptide BPC 157" / "body protection compound 157" / "PL-14736"), ClinicalTrials.gov (NCT02637284 and BPC-157 trial search), plus regulator and anti-doping pages (USADA, Sport Integrity Canada, WADA list references).

Inclusion: published peer-reviewed papers, one conference abstract (flagged as such), registry records, official regulator/anti-doping pages.

One additional registry ID (NCT07437547) surfaced during review but could not be verified against ClinicalTrials.gov and was deliberately excluded from the records above, consistent with the source profile's exclusion of unverifiable IDs.

Exclusion: vendor pages, forum anecdotes, marketing reviews, and secondary blogs, used only to locate primary records, never as evidence.

The key negative finding, no published human efficacy RCT, was checked against the 2025 systematic review and 2026 translational reviews, which independently report the same gap.

Every material conclusion traces to a cited reference. Where evidence is absent, the section says so rather than implying an answer.

Contributors

Written by the Evidence Research Team (a collective editorial byline; no individual credentials are claimed).

Scientific reviewer: not yet assigned (this profile is a draft; scientific review is pending).

Publishing editor: not yet assigned (editorial review is pending).

No external funding was involved in this profile.

Dates

Literature-search date: 2026-10-05.

Profile drafted: 2026-10-05.

Scientific review date: pending (draft, not yet scientifically reviewed).

Scheduled reassessment: set once published, per the site's review cadence.

Corrections

Spotted something we should check? Send us the source: /corrections/.

Substantive changes will be logged here with dates; cosmetic edits will not reset the review date.

2026-10-06: Independent repair pass on reviewer findings. Added the full citation for the 12-patient interstitial-cystitis pilot (Lee, Walker & Ayadi, 2024 PMID 39325560); named the 2026 translational review inline (Mateescu et al., Pharmaceutics PMID 42198317); added two verified registry records (NCT07803250, University of Arkansas rotator-cuff pilot, registered September 2026; NCT07752381, industry-sponsored gummy study, completed November 2025, no results posted); updated the US compounding section for the July 2026 PCAC advisory vote (recommendation only, no FDA rule, compounding still unauthorized) and the August 2026 FDA warning letters. One additional reviewer-flagged registry ID could not be verified against ClinicalTrials.gov and was deliberately not added to the records above.